Myelodysplastic Syndrome with Excess Blasts-2
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome with Excess Blasts-2.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 [Phase 3]
A Phase III clinical trial is investigating induction and consolidation chemotherapy with venetoclax for newly diagnosed acute myeloid leuke…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies [Phase 1]
Hu8F4 is being studied in a Phase 1 trial for multiple advanced hematologic malignancies; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of Tuspetinib (HM43239) in patients…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]
BXCL701 is being studied in a Phase 1 trial for relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2,…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy [Phase 3]
Phase 3 clinical trial update comparing gilteritinib versus midostaurin in combination with induction, consolidation, and maintenance in adu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy [Phase 3]
A Phase 3 clinical trial evaluating the combination of IDH1 inhibitor ivosidenib or IDH2 inhibitor enasidenib with induction and consolidati…
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease [Phase 2]
Phase 2 trial comparing CPX-351 to immediate stem cell transplantation for high-grade myeloid cancers with measurable residual disease was t…
-
CLINICAL_TRIALS trial_result · 2021-03-22Clinical Trial Update: Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms [Phase 2]
Phase 2 trial evaluating early allogeneic hematopoietic cell transplantation for patients with relapsed or refractory high-grade myeloid neo…
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 [Phase 2]
Phase 2 trial evaluating vosaroxin with azacitidine for newly diagnosed acute myeloid leukemia or Myelodysplastic Syndrome with excess blast…